FDA Approves Harvoni for Expanded Use

On Thursday, Gilead Sciences announced that the FDA has approved expanded use of the hepatitis C treatment Harvoni. Harvonis can now be used to treat patients who have chronic hepatitis C infection genotypes 4, 5 and 6 , as well as patients who are co-infected with HIV.

In addition, the FDA approved a combination therapy of Harvoni plus ribavirin for 12 weeks as an alternate therapy to Harvoni treatment for 24 weeks in treatment-experienced, patients with genotype 1 who also have cirrhosis.

Study results showed that about 93% of the patients with these subtypes of the virus and 96% of patients co-infected with HIV showed a sustained response to the virus within 12 weeks of treatment.

Harvoni was first approved for the treatment of chronic HCV genotype 1 infection in adults in the US in October 2014.1-2

View References